Cadrenal Therapeutics, Inc. (CVKD)

Cadrenal Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Selling, General & Admin	6.75	3.55	2.52
Research & Development	4.21	4.08	0.43
Operating Expenses	10.96	7.63	2.95
Operating Income	-10.96	-7.63	-2.95
Interest Expense	-	-0.02	-0.12
Interest & Investment Income	0.31	0.25	0
Other Non Operating Income (Expenses)	-	-0.22	-4.26
EBT Excluding Unusual Items	-10.65	-7.62	-7.32
Other Unusual Items	-	-0.74	-
Pretax Income	-10.65	-8.36	-7.32
Net Income	-10.65	-8.36	-7.32
Net Income to Common	-10.65	-8.36	-7.32
Shares Outstanding (Basic)	1	1	1
Shares Outstanding (Diluted)	1	1	1
Shares Change (YoY)	35.59%	70.99%	-
EPS (Basic)	-8.73	-9.29	-13.92
EPS (Diluted)	-8.73	-9.29	-13.92
Free Cash Flow	-7.36	-3.53	-1.32
Free Cash Flow Per Share	-6.04	-3.93	-2.50
EBITDA	-10.96	-7.63	-2.95
D&A For EBITDA	0	0	0
EBIT	-10.96	-7.63	-2.95

Updated Mar 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q